Highest-materiality recent filing
Moderna Q2 net loss $(0.8)B, EPS $(1.97); norovirus vaccine misses interim endpoint
Q2 revenue $145M (flat YoY); GAAP net loss $(0.8)B, EPS $(1.97) vs $(2.13) in Q2 2025.
Moderna Q1 2026 revenue $389M, GAAP net loss $(1.3)B including $0.9B litigation charge
Revenue $389M (+$281M YoY); ~80% from international; GAAP EPS $(3.40) vs $(2.52) YoY.
Moderna to pay $950M noncontingent lump sum by July 8, 2026 to resolve worldwide patent litigation over Spikevax and mRESVIA.
Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B
Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).
Moderna receives FDA Refusal-to-File for flu vaccine mRNA-1010; no impact on 2026 guidance
FDA CBER refused to review BLA for mRNA-1010 citing comparator choice, not safety/efficacy.
2025 preliminary revenue ~$1.9B ($100M above midpoint); GAAP OpEx $5.0-5.2B (improved $200M).
Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026
2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.
Moderna enters $1.5B credit facility with Ares; $600M initial term loan, $900M delayed draw
$1.5B facility: $600M initial term loan and $900M delayed draw tranche available through Nov 2027/2028.
Moderna targets up to 10% revenue growth in 2026; closes $1.5B loan facility
Targets up to 10% revenue growth in 2026; expanding seasonal vaccine franchise to up to six approved products by 2028.
Moderna Q3 net loss $200M, revenue $1.0B down 45% YoY; narrows 2025 guidance
Q3 revenue $1.0B (down 45% YoY); net loss $(0.51)/share vs. EPS $0.03 in Q3 2024.
Moderna Q2 net loss $0.8B, rev $142M (-41% YoY); cuts 2025 revenue guidance high end by $300M
Q2 revenue $142M (-41% YoY); GAAP net loss $0.8B ($2.13 EPS loss).
Moderna Q1 net loss $1.0B, revenue $108M; reiterates 2025 revenue guidance $1.5-2.5B
Q1 2025 revenue $108M (down 35% YoY); GAAP net loss $(1.0)B, EPS $(2.52).
Q4 net loss $1.1B, EPS $(2.91); FY2024 revenue $3.2B falls 53%; guides 2025 rev $1.5-2.5B
Q4 revenue $1.0B (-66% YoY); GAAP net loss $1.1B vs net income $217M in Q4 2023.
2024 product sales ~$3.0-3.1B (unaudited); cash & investments ~$9.5B. Full 2024 results due Feb 14, 2025.
Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B
GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.
Expects ten product approvals through 2027, including three respiratory vaccine submissions in 2024 (next-gen COVID, flu/COVID combo, RSV for high-risk adults).
Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B
Revenue $241M vs $344M YoY; net product sales $184M (-37%).
Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B
GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.
Moderna Q4 2023 revenue $2.8B, EPS $0.55; FY net loss $4.7B from $3.7B non-cash charges
Q4 revenue $2.8B (-43% YoY); GAAP net income $217M, diluted EPS $0.55.
2023 COVID-19 vaccine product sales ~$6.7B (incl. $0.6B deferred revenue from GAVI).
Moderna CCO Arpa Garay departs; CEO & President to oversee commercial org
Arpa Garay no longer serves as Chief Commercial Officer effective Dec 8, 2023.
Moderna Q3 net loss $3.6B on $1.8B revenue; guides 2024 sales ~$4B, aims for 2026 breakeven
Q3 revenues $1.8B, down 44% YoY; net loss $3.6B vs net income $1.0B; diluted EPS -$9.53.
Immatics receives $120M upfront plus research funding; milestones could exceed $1.7B plus tiered royalties on net sales.
Moderna Q2 net loss $1.4B, EPS -$3.62; revenue $344M (-93% YoY); FY23 sales guidance $6-8B
Q2 revenue $344M vs $4.7B YoY; product sales $293M, down 94% due to lower COVID vaccine volume.
Moderna Q1 revenue $1.9B, net income $79M, reiterates $5B FY sales guidance
Q1 revenue $1.9B (down 69% YoY); GAAP net income $79M ($0.19 EPS) vs $3.7B ($8.58 EPS) in Q1 2022.
Moderna Q4 net income down 70% to $1.5B; FY2022 revenue $19.3B; reiterates $5B COVID sales for 2023
Q4 2022 revenue $5.1B (down 29% YoY from $7.2B); GAAP diluted EPS $3.61 (down 68% from $11.29).
Moderna reports prelim 2022 COVID sales $18.4B; reiterates 2023 $5B min; RSV study accrues cases
Prelim 2022 COVID vaccine sales ~$18.4B; R&D ~$3.3B; cash & investments >$18B.
RSV vaccine Phase 3 enrolled >36,000 of 37,000 target; flu vaccine efficacy trial initiated in Northern Hemisphere.
mRNA-4157/V940 + KEYTRUDA reduced risk of recurrence or death by 44% vs KEYTRUDA alone (HR=0.56, p=0.0266) in stage III/IV melanoma.
Moderna Q3 net income $1.0B, EPS $2.53; lowers 2022 sales view to $18-19B
Q3 revenue $3.4B (down 32% YoY), GAAP net income $1.0B, diluted EPS $2.53 (down 67%).
Moderna appoints James Mock as CFO effective Sept 6, 2022; David Meline retires
James Mock named CFO, starting Sept 6, 2022; will report to CEO Stéphane Bancel.
Moderna Q2 revenue $4.7B, GAAP EPS $5.24, announces $3B buyback, reiterates ~$21B 2022 sales outlook
Q2 revenue $4.7B vs $4.4B YoY; GAAP net income $2.2B ($5.24 diluted EPS) vs $2.8B ($6.46) YoY.
Moderna CFO David Meline to retire by Dec 31, 2022; will serve as consultant through Mar 2026
David Meline continues as CFO until Dec 31, 2022 (or earlier if successor starts); consulting services to Mar 2, 2026.
Moderna CEO Bancel amends 10b5-1 plan to exercise 4.6M options; expects to donate $355M proceeds
CEO Bancel amended 10b5-1 plan to exercise 4,587,155 shares at $0.99/share (option from 2013, expiring Aug 2023).
Moderna enters separation agreement with former CFO; includes clawback tied to Dentsply probe
CFO Jorge Gomez departed May 10; separation agreement signed May 13, 2022.
Moderna CFO Jorge Gomez departs amid Dentsply Sirona investigation; David Meline returns as CFO
Jorge Gomez terminated as CFO effective May 10, 2022, after former employer Dentsply Sirona disclosed an internal investigation.
Moderna Q1 revenue $6.1B, net income $3.7B; reiterates $21B 2022 APAs
GAAP diluted EPS of $8.58 vs $2.84 YoY; revenue tripled to $6.1B from $1.9B.
Moderna appoints Jorge Gomez as CFO; David Meline to retire effective May 9, 2022
Jorge Gomez appointed CFO effective May 9, 2022, reporting to CEO Stéphane Bancel.
On September 28, 2024, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Abbas Hussain to the Board, effective October 2, 2024.
On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.
On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.
On July 19, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed David M. Rubenstein to the Board, effective August 5, 2024.
Arpa Garay, the Company’s Chief Commercial Officer, will be departing the Company, and that effective as of December 8, 2023, Ms. Garay will no longer serve in that role or as an executive officer of the Company.
On September 29, 2022, Moderna, Inc. (the “Company”) announced that Juan Andres, the Company’s Chief Technical Operations and Quality Officer, will transition into a new role as President, Strategic Partnerships and Enterprise Expansion of the Company, effective January 1, 2023.
The Company further announced that Dr. Jerh Collins, Ph.D., who will join the Company on O ctober 3, 2022, will assume the role of Chief Technical Operations and Quality Officer of the Company, effective January 1, 2023.
David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.
James Mock has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning September 6, 2022.
Mr. Meline’s continued service as Chief Financial Officer of the Company and his voluntary retirement from the Company on December 31, 2022
Jorge Gomez departed from the role of Chief Financial Officer of the Company
David Meline, the Company’s recently retired Chief Financial Officer, will continue as Chief Financial Officer, effective May 11, 2022.
Max materiality 0.85 · Median 0.75 · Most common event earnings